Document is current

Article History

Received: 6 November 2018

Accepted: 3 April 2019

First Online: 9 May 2019

Ethics approval and consent to participate

: The MESEMS trial conducted in Italy was approved by the Ethics Committee of “Azienda Ospedaliera Universitaria S. Martino di Genova” on May 30, 2012.All trials belonging to the MESEMS network have obtained approval by local Ethical Committees.Written informed consent will be obtained from all study participants.

: Antonio Uccelli has received personal compensation from Novartis, TEVA, Biogen, Merck, Roche and Genzyme for public speaking and advisory boards.Alice Laroni has received personal compensation from Novartis, Sanofi Genzyme, Biogen, Merck, Roche, and TEVA for public speaking and advisory boards.Lou Brundin has received travel grants and lecturing fees from Sanofi/ Genzyme, Biogen, and Amirall and has participated in advisory boards for Genzyme, Sanofi, Biogen, Amirall, and Merck. Brundin has grants from Swedish medical research foundation, the Brain foundation, Stockholm Council, and Karolinska Instituet.Michel Clanet: no conflict of interest to declare.Oscar Fernandez, has received honoraria from Actelion, Allergan, Almirall, Bayer Schering, Biogen, Merck Serono, Novartis, Roche, and Teva.Seyed Massoud Nabavi has received honoraria from, Biogen, Bayer, Genzyme,, Merck Serono, Novartis, Sanofi, Abidi Co., Zist daru Co., Actoverco Co. as PI of trials grants or speaker bureau.Paolo Muraro reports no conflict of interest. He discloses travel support and speaker honoraria from Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono, and Sanofi Aventis.Roberto S. Oliveri is currently a full-time employee at Genmab.Ernst Radue: no conflict of interest to declare.Johann Sellner received support for attending scientific conferences, advisory boards, lectures and consultancy within the last 12 months from Bayer, Biogen, MedDay, Merck, Novartis, Roche, Sanofi-Genzyme.Per Soelberg Sorensen has received personal compensation for serving on scientific advisory boards, steering committees, or independent data monitoring boards for Biogen, Merck, Novartis, TEVA, GlaxoSmithKline, MedDay Pharmaceuticals, Genzyme, Celgene, and Forward Pharma and has received speaker honoraria from Biogen, Merck, Teva, Genzyme, and Novartis. His department has received research support from Biogen, Merck, TEVA, Novartis, Sanofi-Aventis/Genzyme, and Roche.Maria Pia Sormani received compensation for serving on the Scientific Advisory Boards of Teva, Genzyme, Novartis, Roche, and Vertex; funding for travel or speaker honoraria from Merck Serono, Teva, Genzyme, Novartis, Biogen, and Roche; consultancy from Merck Serono, Biogen, Teva, Genzyme, Roche, GeNeuro, MedDay, and Novartis; Speakers’ Bureaus from Teva, Merck Serono, Biogen, Novartis, and Genzyme.Jens Thomas Wuerfel is CEO of MIAC AG, Switzerland. He served on advisory boards for Actelion, Biogen, Genzyme-Sanofi, Novartis, and Roche. He received funds from EU (Horizon2020), the German Research Foundation (DFG), the German Ministeries of Science and Economy (BMBF, BMWi) unrelated to this study.Mario Alberto Battaglia has nothing to disclose.Mark S. Freedman has received honoraria from Actelion, Biogen, Bayer, Celgene, Chugai, EMD Inc., Genzyme, Hoffman La Roche, Merck Serono, Novartis, Pendopharm, Sanofi, and Teva; grants from Genzyme and is on the Genzyme speakers’ bureau.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.